soul trial oral semaglutide cardiovascular outcomes 2024 2025 results

soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Updates in Medicine on X: "SOUL (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in soul trial oral semaglutide cardiovascular

Name: soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Updates in Medicine on X: "SOUL (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in soul trial oral semaglutide cardiovascular
Brand: eric-jean.com
SKU: 14057310605
Price: 24.80 USD
Availability: InStock
Rating: 4.7155000000000005 (20 reviews)

SKU: 14057310605

4.7

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Sep 28 - Oct 3

Description

Using a search terms GLP-1 and MODS, four articles were identified

soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Updates in Medicine on X: "SOUL (NEJM 2025): led to a 14% in major CV events vs placebo in T2DM with ASCVD or CKD no in soul trial oral semaglutide cardiovascular

Many people taking Ozempic or other GLP-1 medications may not eat enough, and studies have found that their diets often lack important nutrients, including iron

It may also benefit individuals with obesity, prediabetes, type 2 diabetes, high blood pressure, PCOS, or other conditions that require careful medical monitoring during treatment